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Heterogeneity in renal cell carcinoma and its impact on prognosis - a flow
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Summary In the process of tumour progression genetic instability is the basis for the evolution of tumour cell
clones with various genotypic and phenotypic characteristics causing heterogeneity. Renal cell carcinoma has a
long prediagnostic growth period, which increases the probability of clonal evolution. We have studied 200
consecutive renal cell carcinomas, addressing the interrelationship between intratumour heterogeneity and
clinicopathological factors. DNA ploidy patterns were analysed in multiple samples from each tumour using
flow cytometry and compared with clinical stage, tumour invasion, metastatic rate and survival. Eighty-five of
192 evaluable tumours (44%) were homogeneous concerning DNA ploidy (62% diploid, 38% aneuploid).
Among 107 heterogeneous tumours a majority (79%) contained aneuploid as well as diploid cell clones.
Homogeneously diploid tumours had a lower incidence of local tumour spread compared with tumours with
aneuploid cell clones (P<0.001), but the frequency of distant metastasis at time of diagnosis was similar. The
presence of aneuploidy in at least one sample from a tumour was a significant adverse prognostic factor
(P<0.001), whereas the degree of heterogeneity had no influence on survival. The frequent heterogeneity
demonstrated indicates that multiple samples must be investigated to evaluate properly the malignant character
of renal cell carcinoma.
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In tumours stepwise genetic changes occur during the course
of the disease. Each step might induce the emergence of a
new subclone with a selective growth advantage (Weiss, 1985;
Vogelstein et al., 1989). This evolution proceeds towards
increased autonomy by a temporal change in various tumour
cell characteristics, where the acquisition or loss of various
phenotypes can be independent of each other (Nicholson,
1987). It is evident that malignant tumours contain a variety
of subpopulations of cells with different invasive and
metastatic capabilities and that increased genetic instability
enhances the rate of tumour progression (Nowell, 1986).
In renal cell carcinoma we have previously demonstrated
heterogeneity regarding DNA ploidy, karyotype, DNA
fingerprint pattern and cell kinetic properties (Larsson et
al., 1993; Ljungberg et al., 1985, 1994; Mehle et al., 1993;
Nordenson et al., 1988). The most powerful prognostic
parameter in renal cell carcinoma is tumour stage but DNA
ploidy and cell kinetic parameters have also been found to be
of predictive value (Baretton et al., 1991; Larsson et al., 1993;
Ljungberg et al., 1994; Skinner et al., 1971). This tumour type
shows a wide spectrum regarding clinical behaviour, from
cases with early metastatic presentation to tumours with
considerable local growth without invasion or distant
manifestations for many years (Skinner et al., 1971,
Ljungberg et al., 1988). At diagnosis renal cell carcinoma
has a mean diameter of approximately 8 cm, indicating a
long prediagnostic tumour growth period. Therefore renal
cell carcinoma provides a model for undisturbed malignant
growth that can give important information regarding clonal
evolution, leading to intratumour heterogeneity, and its
clinical significance. Although heterogeneity is well recog-
nised in many tumours, no data are available regarding the
possible impact of this phenomenon for prognosis.
In the present study a series of 200 renal cell carcinomas
was analysed concerning intratumour heterogeneity, judged
by DNA ploidy analysis, and its influence on clinicopatho-
logical parameters, including outcome for the patients, was
evaluated.
Materials and methods
Patients
From 1982 to 1993, 231 patients were hospitalised at the
Department of Urology, University Hospital, Umea, with a
histological diagnosis of renal cell carcinoma. Thirty-one
patients received palliative treatment only due to advanced
metastatic spread as these patients were not suitable for
surgery of metastases or for immunotherapy. The remaining
200 patients (87%) were surgically treated and included in the
study, 195 with radical perifascial nephrectomy, three with
partial resection and two patients with bilateral resections.
There were 123 men and 77 women, with a mean age of 64.7
years, ranging from 25 to 86 years. The patients were staged
according to Robson et al. (1969). Preoperatively, the
patients were examined with chest radiography, ultrasound
and computerised tomography and, in patients with
symptoms or signs of bone metastases, with bone scans.
The perifascial nephrectomies were performed en bloc with
kidney, perirenal fat and Gerota's fascia, including all tissue
from the midline of the aorta in left-sided tumours and from
the midline of the vena cava in right-sided tumours. In cases
with enlarged or palpable lymph nodes between the aorta and
the cava lymph node dissections were performed. Radical
retroperitoneal lymph node dissections were not performed.
The patients were followed up according to a programme
including clinical and radiological examinations. In October
1994, the mean follow-up time for alive patients was 57.8
months (median 53.0, range 3-142 months).
Tumours
The tumour specimens were obtained by schematically taken
biopsies from the nephrectomised kidney with tumour and
kidney cortex samples (Ljungberg et al., 1985). From each
tumour generally six (4-8) samples were taken, and from
each sample one part was processed for flow cytometric DNA
analysis and another part for conventional histopathological
examination. Histopathological grade was defined according
to Skinner et al. (1971). The examination included, apart
from the six (4-8) tumour samples primarily taken,
microscopical evaluation of local tumour invasion using the
parameter's sharp or diffuse demarcation of the tumour to
adjacent kidney cortex tissue, through the renal capsule into
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the perirenal fat and presence of tumour invasion into major
veins in the hilar region. Histopathologically diffuse or
infiltrating demarcation of the tumour to adjacent tissues
was judged as one feature of local invasion.
DNA analysis
The method for flow cytometric DNA analysis has been
described previously (Ljungberg et al., 1985). Briefly, the
fresh samples were minced and stained using a propidium
iodide solution. After staining the samples were filtered and
run in a flow cytometer. During the course of this project
different flow cytometers were used, a model 4800A
cytofluorograph (Biophysics System, NY, USA) from 1982
to 1985 a FACS Analyzer (Becton-Dickinson Immunocyto-
metry Systems, CA, USA) from 1985 to 1987 and a
FACScan (Becton-Dickinson) 1987 to 1993. The kidney
cortex tissue samples were used as standards for diploidy.
The tumour samples were denominated diploid (DNA
index= 1.0) when only one peak was detected, and aneuploid
when two separate peaks were found, as it was assumed that
all tumour samples contained normal as well as tumour cells.
A tumour sample was regarded as tetraploid when more than
15% of the cells had a tetraploid DNA index (1.95-2.05). In
most samples trout and chicken erythrocytes were added and
used as reference cells. A difference in DNA index of 0.3 or
more between the different tumour samples was used as a
limit for classifying the samples of a tumour as belonging to
different cell clones. A tumour was denominated diploid
when all tumour samples had a diploid DNA index (0.95-
1.05), and aneuploid when at least one aneuploid tumour cell
clone was found. DNA ploidy could not be evaluated in three
tumours as a result of necrosis, and in five as a result of
missed sampling of fresh tumour material. Thus, a total of
192 tumours were analysed and included in the study. Only
three tumours were homogeneously tetraploid or tetraploid/
diploid and were referred to the aneuploid group in the
statistical analysis.
Statistics
For statistical analysis the Fisher's exact probability test was
used. A P-value less than 0.05 was considered as statistically
significant. The survival time calculations were illustrated
with Kaplan-Meier curves and compared with the log-rank
test. The probability of obtaining an aneuploid sample in a
tumour was calculated by using Bayes' theorem and the
theorem on total probability.
Results
DNA ploidy and heterogeneity
The distribution of DNA ploidy levels in the tumours is
shown in Table 1. Fifty-three tumours (28%) were
homogeneously diploid and 32 (17%) were homogeneously
aneuploid. Thus, 85 out of 192 renal cell carcinomas (44%)
had a homogeneous DNA content. Heterogeneity conceming
DNA ploidy was present in the remaining 107 renal cell
carcinomas (56%), 81 tumours demonstrated both diploid
and aneuploid tumour samples and 26 tumours had two or
more different aneuploid cell clones (Table I).
DNA ploidy and tumour spread
The distribution of DNA ploidy in relation to tumour stage
is shown in Table II. A majority of the homogeneously
diploid tumours were in stage I (60%), in contrast to the
aneuploid tumours (35%) whereas the fractions of stage IV
tumours were similar (23% and 34% respectively). In the
aneuploid tumours, stage I and stage IV tumours were
equally distributed. Diploid tumours differed significantly
from tumours bearing aneuploid clones regarding local
tumour invasion properties (Table III). However, the
frequency of primary synchronous metastases was similar
for all ploidy groups, while there was a significantly higher
Table I Intratumoral distribution of DNA ploidy within 192 renal
cell carcinomas
DNA ploidy Number %
Homogeneous tumours
Diploid 53 28
Aneuploid 32 17
No. 85 44
Heterogeneous tumours
Diploid + 1 aneuploid clone 45 23
Diploid + 2 aneuploid clones 32 17
Diploid + >3 aneuploid clones 4 2
2 aneuploid clones 16 8
)>3 aneuploid clones 10 5
No. 107 56
Total 192 100
Table II Distribution of DNA ploidy in relation to clinical
stage in 192 patients with renal cell carcinoma
Diploid Aneuploid Total
Stage No. (%) No. (%) No. (%)
I 32 (60) 48 (35) 80 (42)
II 2(4) 7(5) 9(5)
Illa 6 (11) 20 (14) 26 (13)
IIIb 1 (2) 17 (12) 18 (9)
IV 12 (23) 47 (34) 59 (31)
Total 53 (28) 139 (72) 192 (100)
Table m Relation between DNA ploidy and occurrence of four different local tumour invasive parameters in 192
patients with renal cell carcinoma. Tumours with regional lymph node metastases and/or ipsilateral adrenal
metastases are grouped together
Diffuse
demarcation
to surrounding Lymph node At least one
Invasion into Invasion through kidney and/or adrenal invasive parameter
DNA renal veins renal capsule parenchyma metastases positive Total
ploidy No. (%o) No. (%) No. (%) No. (%) No. (%) No.
D 8 15 4 8 6 11 3 6 12 23 53
D/A 34*** 42 35*** 43 39*** 48 21** 26 52*** 64 81
A 12* 38 14*** 44 17*** 53 9* 28 20*** 63 32
A/A 13** 50 12*** 46 17*** 65 NS 4 15 20*** 77 26
D, homogeneously diploid tumours; D/A, heterogeneous tumour with diploid and aneuploid tumour samples; A,
homogeneously aneuploid tumours; A/A, heterogeneously aneuploid tumours. P-values given refer to comparisons
between the group of homogeneously diploid tumours and the different groups of tumours having aneuploidy;
*P<0.05; **P<0.01; ***P<0.001. NS, not significant.Heterogeneity in renal cell carcinoma
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Table IV Relation between DNA ploidy and the occurrence ofdistant metastases
Patients with Stage I-IIIpatients Total no. ofpatients
primary metastases with secondary with occurrence of
DNA (stage IV) metastases metastases Total
ploidy No. (%) No./No. at risk (%) No. (%) No.
D 12 (23) 5/41 (12) 17 (32) 53
D/A 32* (40) 18/49** (37) 50*** (62) 81
A 7 NS (22) 10/25* (40), 17* (53) 32
A/A 8 NS (31) 8/18*** (44) 16* (62) 26
D, homogeneously diploid tumours; D/A, heterogeneous tumour with diploid and
aneuploid tumour samples; A, homogeneously aneuploid tumour; A/A, heterogeneously
aneuploid tumours. P-values given refer to comparisons between the group of
homogeneously diploid tumours and the different groups of tumours having
aneuploidy; *P<0.05; **P<0.01; ***P<0.001. NS, not significant.
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Figure 1 Kaplan-Meier survival curves of 191
renal cell carcinoma subdivided into patients with
diploid (D) tumours (. --), heterogeneously dij
(D/A) tumours (- ), homogeneously aneuplc
(....) and heterogeneously aneuploid (A/A) tumi
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Figure 2 The probability of detecting an aneuploid cell clone by
taking a random biopsy in an aneuploid renal cell carcinoma,
plotted against the number of random tumour samples analysed.
intercurrent diseases. The mean survival time was 23 months
for patients dead of the disease and 33 months for patients
dead of intercurrent diseases. Patients with diploid tumours
survived significantly longer compared with patients having
aneuploid tumours (P<0.001, Figure la). Similar data were
found for patients without distant metastases (stages I-III,
P<0.001, Figure lb), as well as for patients with distant
150 180 metastases at diagnosis (stage IV, P<0.002, Figure 1c). There
were no differences in survival times for patients with
homogeneously aneuploid, heterogeneously aneuploid or
diploid/aneuploid tumours, irrespective of stage.
2 patients with By taking only one random tumour sample, the
homogeneously probability of obtaining the aneuploid DNA pattern in
oid (A) tumours
tumour having aneuploid cell clones was 69% as calculated
os(A) by using Bayes' theorem and the theorem on total probability
rd 26 A/A. (b) (Figure 2). At least four tumour samples were needed to
nd 18 A/A. (c) achieve more than 90% probability of detecting aneuploidy.
,A/A.
Discussion
frequency of metachronous metastases in patients with
aneuploid tumours (Table IV). Tumours with aneuploidy
were significantly larger than homogeneously diploid tumours
(mean diameter 87 +34 mm and 62+28 mm respectively,
P<0.001).
Survival
Seventy-one of the 192 patients (37%) were alive, 94 (49%)
had died of the disease and 27 (14%) were dead owing to
It is well recognised that tumours frequently consist of
subpopulations with different genotypes and phenotypes,
including cell clones with differences in DNA ploidy.
Previously a considerable heterogeneity has been reported
for DNA ploidy in renal cell carcinoma (Bringuier et al.,
1993; Ljungberg et al., 1988; Masters et al., 1992), which was
further substantiated in the present study showing hetero-
geneity in 56% of the tumours. The heterogeneity in renal
cell carcinoma can be demonstrated on many levels as seen in
our earlier published data on cytogenetic features and DNA
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fingerprinting patterns (Mehle et al.. 1993; Nordenson et al..
1988). Intratumour heterogeneity regarding DNA ploidy has
also been described for other tumours. such as breast cancer
(Barranco et al.. 1994; Beerman et al.. 1991; Fern6 et al..
1992). gastrointestinal carcinoma (Hiddeman et al., 1986;
Sasaki et al.. 1988), oesophageal squamous cell carcinoma
(Sasaki et al., 1991) and bladder carcinoma (Norming et al..
1992). However, in the present study the clinical relevance of
heterogeneity was also documented and evaluated.
The renal cell carcinoma material presently studied is
unique in its size and together with a thorough characterisa-
tion of clinicopathological parameters was used as a basis for
analysis of the clinical impact of intratumour heterogeneity.
The heterogeneity itself seemed to have no prognostic
significance. The most significant result was the finding that
aneuploidy within a tumour was a strong prognostic
indicator, and predictive value was found even if aneuploidy
was demonstrated in only one sample of a tumour. The
degree of heterogeneity within aneuploid tumours did not
influence the prognosis and did not predict any clinical
parameter. The prognostic relevance was shown both for
patients without metastases as well as for patients with
distant metastases at diagnosis. Local invasive behaviour and
spread was also related to the DNA ploidy level, which is in
line with a report on a smaller series of tumours (Ljungberg
et al., 1988). There was also a difference between diploid and
aneuploid tumours regarding the occurrence of distant
metastases. although distant metastases at the time of
diagnosis were demonstrated in almost the same frequency
in both groups. Thus, it is obvious that subclones of tumour
cells defined by their DNA ploidy character had different
invasive and metastatic capabilities, which could explain the
differences seen regarding survival.
An association between DNA ploidy and tumour cell
kinetics has been reported with lower S-phase fractions and
longer potential tumour doubling times (Tpo,) in diploid
compared with aneuploid clones (Baretton et al.. 1991;
Larsson et al., 1993; Ljungberg et al.. 1994). In a study of
in vivo labelling with iododeoxyuridine the shortest Tpot value
detected within a tumour was of high prognostic significance
(Ljungberg et al.. 1994). In the present study, tumours with
aneuploidy were larger than diploid tumours. These data
indicate a connection between aneuploidy. high growth rate
and a tendency for local spread and progressive disease. In
contrast, diploid tumour cell clones had a lower proliferation
rate and metastasised later in the disease history.
It is obvious from the data presented here that multiple
sampling is mandatory in order to properly evaluate the
malignant potential of a renal cell carcinoma owing to the
high degree of heterogeneity present. In a previous study
analysing only one tumour sample. DNA ploidy of the
primary tumours gave no prognostic information (Ljungberg
et al.,. 1986). We recommend that at least four different
samples should be analysed separately in each primary
tumour to secure at least a 90% probability of obtaining
aneuploidy. Another approach to evaluating heterogeneous
tumours is to use a mixture of different samples as suggested
by Barranco et al., (1994). However, owing to dilution a
small aneuploid clone could be undetected using the mixture
approach. The evaluation of molecular genetic characteristics
might also be improved by separate analysis of multiple
samples as illustrated by DNA fingerprint patterns, telomere
length fragment determinations (Mehle et al., 1993, 1994) and
analysis of polymorphic microsatellite markers (unpublished
data).
In the present study heterogeneity itself. evaluated by
DNA ploidy, had no prognostic significance in renal cell
carcinoma. Multiple sampling is essential to reveal aneuploi-
dy with a high probability. The presence of aneuploidy within
a tumour is a main predictive parameter associated with high
proliferation. local tumour invasion and poor prognosis. The
more precise genetic events responsible for these tumour
features have yet to be charactenrsed.
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